DOCSLIB.ORG

Curcumin Blocks Prostaglandin E2 Biosynthesis Through Direct Inhibition of the Microsomal Prostaglandin E2 Synthase-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Curcumin Blocks Prostaglandin E2 Biosynthesis Through Direct Inhibition of the Microsomal Prostaglandin E2 Synthase-1 Published OnlineFirst August 11, 2009; DOI: 10.1158/1535-7163.MCT-09-0290 2348 Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1 Andreas Koeberle,1 Hinnak Northoff,2 anti-inflammatory activities. [Mol Cancer Ther 2009;8 and Oliver Werz1 (8):2348–55] 1Department of Pharmaceutical Analytics, Pharmaceutical Institute, University of Tuebingen, and 2Institute for Clinical and Introduction Experimental Transfusion Medicine, University Medical Center Curcumin (diferuloylmethane; Fig. 1), an antioxidant poly- Tuebingen, Tuebingen, Germany phenol from Curcuma longa (tumeric), is a major ingredient of the curry spice tumeric and has been used for the therapy Abstract of inflammatory and infectious diseases in ayurvedic med- icine. Results from preclinical and clinical studies indicate Prostaglandin E (PGE ) plays a crucial role in the apparent 2 2 chemopreventive, antiproliferative, proapoptotic, antimeta- link between tumor growth and chronic inflammation. Cy- static, antiangiogenic, and anti-inflammatory effects of cur- clooxygenase (COX)-2 and microsomal PGE synthase-1, 2 cumin (for review, see refs. 1, 2). The pleiotropic activities of which are overexpressed in many cancers, are functional- curcumin are supposed to be linked to its interference with ly coupled and thus produce massive PGE in various tu- 2 the expression or activation of multiple key signaling mole- mors. Curcumin, a polyphenolic β-diketone from tumeric cules, including peroxisome proliferator–activated receptor with anti-carcinogenic and anti-inflammatory activities, γ, p53, nuclear factor-E2–related factor, nuclear factor κB was shown to suppress PGE formation and to block the 2 (nuclear factor κB), activator protein-1, protein kinase C, expression of COX-2 and of microsomal PGE synthase-1. 2 protein kinase A, focal adhesion kinase, protein kinase B, Here, we identified microsomal PGE synthase-1 as a mo- 2 tumor necrosis factor-α,interleukin1β, chemokines, p300 lecular target of curcumin and we show that inhibition of histone acetyl transferase, cyclooxygenase (COX)-2, 5-lipox- microsomal PGE synthase-1 activity is the predominant 2 ygenase, and matrix metalloproteinase-9 (1, 2). Numerous mechanism of curcumin to suppress PGE biosynthesis. 2 molecular targets of curcumin have been identified thus Curcumin reversibly inhibited the conversion of PGH to 2 far, including COX-1 (IC =25–50 μmol/L;refs.3,4),5- PGE by microsomal PGE synthase-1 in microsomes of 50 2 2 lipoxygenase (IC =0.7μmol/L; ref. 3), glycogen synthase interleukin-1β–stimulated A549 lung carcinoma cells with 50 kinase-3β (IC = 0.07 μmol/L; ref. 5), DNA topoisomerase an IC of 0.2 to 0.3 μmol/L. Closely related polyphenols 50 50 II (at 50 μmol/L; ref. 6), inhibitor of NFκBkinase(IC = (e.g., resveratrol, coniferyl alcohol, eugenol, rosmarinic 50 20 μmol/L; ref. 7), protein kinase C (IC =15μmol/L; acid) failed in this respect, and isolated ovine COX-1 and 50 ref. 8), and xanthine oxidase (IC = 200–400 μmol/L). How- human recombinant COX-2 were not inhibited by curcu- 50 ever, many of these interactions are characterized by low minupto30μmol/L. In lipopolysaccharide-stimulated affinities as reflected by the respective high IC values in human whole blood, curcumin inhibited COX-2–derived 50 functional assays, and the pharmacologic relevance of most PGE formation from endogenous or from exogenous 2 of these target interactions is uncertain. arachidonic acid, whereas the concomitant formation of Prostaglandin E (PGE ) is a potent lipid mediator that is COX-2–mediated 6-keto PGF α and COX-1–derived 12(S)- 2 2 1 closely linked to inflammation and cancer. The biosynthesis hydroxy-5-cis-8,10-trans-heptadecatrienoic acid was sup- of PGE requires transformation of arachidonic acid by pressed only at significant higher concentrations. Based 2 COX-1 or COX-2 [enzyme commission (EC) 1.14.99.1] to on the key function of PGE in inflammation and carcinogen- 2 PGH , which is subsequently converted by PGE synthases esis, inhibition of microsomal PGE synthase-1 by curcumin 2 2 2 (EC 5.3.99.3) to PGE (9). Whereas the cytosolic PGE provides a molecular basis for its anticarcinogenic and 2 2 synthase is constitutively expressed and preferentially couples to COX-1, the microsomal PGE2 synthase-1 is functionally linked to COX-2. COX-2 and microsomal PGE2 synthase-1 Received 3/27/09; revised 5/19/09; accepted 5/20/09; published are induced by proinflammatory stimuli, and both enzymes OnlineFirst 8/11/09. are overexpressed in various cancers (9, 10). Curcumin was Grant support: Deutsche Forschungsgemeinschaft (WE 2260/8-1). – shown to lower PGE2 formation in cellular models (3, 11 14), The costs of publication of this article were defrayed in part by the – payment of page charges. This article must therefore be hereby marked in whole blood (15), and in vivo (16 19). Besides direct inhibi- – μ advertisement in accordance with 18 U.S.C. Section 1734 solely to tion of COX-1 and -2 (IC50 =25 50 mol/L for COX-1 and indicate this fact. >50μmol/L for COX-2 (3, 4)), impaired activation of activa- Requests for reprints: Oliver Werz, Department of Pharmaceutical Analytics, tor protein-1 and the NFκB signaling pathway, resulting in Pharmaceutical Institute, University of Tuebingen, Auf der Morgenstelle 8, D-72076 Tuebingen, Germany. Phone: 49-7071-2978793; reduced expression of COX-2 (13, 20) and microsomal Fax: 49-7071-294565. E-mail: [email protected] PGE2 synthase-1 (11), might be responsible. However, the Copyright © 2009 American Association for Cancer Research. effects of curcumin on prostanoid biosynthesis are diverse, doi:10.1158/1535-7163.MCT-09-0290 depending on the distinct assays used. For example, the Mol Cancer Ther 2009;8(8). August 2009 Downloaded from mct.aacrjournals.org on September 24, 2021. © 2009 American Association for Cancer Research. Published OnlineFirst August 11, 2009; DOI: 10.1158/1535-7163.MCT-09-0290 Molecular Cancer Therapeutics 2349 Figure 1. Structure of curcumin and related polyphenols. α μ conversion of arachidonic acid to PGD2 and PGF2 was penicillin (100 U/mL), and streptomycin (100 g/mL) at blocked in epidermal microsomes (21), but curcumin in- 37°C in a 5% CO2 incubator. After 3 d, confluent cells α creased the formation of PGF2 and the stable PGI2 degra- were detached using 1× trypsin/EDTA solution and reseeded α β– 6 2 dation product 6-keto PGF1 in interleukin-1 stimulated at 2 × 10 cells in 20 mL medium in 175-cm flasks. A549 cells (11). Here, we identified microsomal PGE2 For isolation of human platelets, venous blood was taken synthase-1 as functional and highly susceptible molecular from healthy adult donors (Blood Center of the University target of curcumin. Our data show that suppression of Hospital Tuebingen) who did not take any medication for at PGE2 biosynthesis in cell-based assays is primarily due to least 7 d, and leukocyte concentrates were prepared by cen- interference with microsomal PGE2 synthase-1 rather than trifugation (4,000 × g; 20 min; 20°C). Cells were immediately with COX enzymes, and this interaction occurs at low con- isolated by dextran sedimentation and centrifugation on centrations that may be achieved in vivo. Nycoprep cushions (PAA). Platelet-rich plasma was ob- tained from the supernatants, mixed with PBS (pH 5.9; 3:2 v/v), and centrifuged (2,100 × g;15min;roomtempera- Materials and Methods ture), and the pelleted platelets were resuspended in PBS Reagents (pH 5.9)/0.9% NaCl (1:1 v/v). Platelets were finally resus- Curcumin, purchased from Sigma-Aldrich was dissolved pended in PBS (pH 7.4) and 1 mmol/L CaCl2. in DMSO and kept in the dark at −20°C, and freezing/thaw- Determination of PGE2 and 6-keto PGF1α Formation in ing cycles were kept to a minimum. The thromboxane Lipopolysaccharide-Stimulated Human Whole Blood synthase inhibitor CV4151 (22) and the microsomal PGE2 Peripheral blood from healthy adult volunteers (see synthase-1 inhibitor 2-(2-chlorophenyl)-1H-phenanthro above) was obtained by venipuncture and collected in sy- [9,10-d]-imidazole were generous gifts by Dr. S. Laufer ringes containing heparin (20 U/mL). For determination α (University of Tuebingen) and Dr. M. Schubert-Zsilavecz of PGE2 and 6-keto PGF1 , aliquots of whole blood (0.8 mL) (University of Frankfurt), respectively. Materials used are were mixed with the thromboxane synthase inhibitor DMEM/high glucose (4.5 g/L) medium, penicillin, strepto- CV4151 (1 μmol/L) and with aspirin (50 μmol/L). A total vol- mycin, and trypsin/EDTA solution (PAA); PGH2 (Larodan); ume of 1 mL was adjusted with sample buffer [10 mmol/L β and 11 -PGE2, PGB1, 3-(3-(tert-butylthio)-1-(4-chlorobenzyl)- potassium phosphate buffer (pH 7.4), 3 mmol/L KCl, 5-isopropyl-1H-indol-2-yl)-2,2-dimethylpropanoic acid (MK- 140 mmol/L NaCl, and 6 mmol/L D-glucose]. After preincu- 886), human recombinant COX-2, and ovine COX-1 (Cayman bation with the indicated compounds for 5 min at room Chemical). All other chemicals were obtained from Sigma- temperature, the samples were stimulated with lipopolysac- Aldrich, unless stated otherwise. charide (10 μg/mL) for 5 h at 37°C. Prostanoid formation Cells was stopped on ice, the samples were centrifuged (2,300 × g; α A549 cells were cultured in DMEM/high glucose (4.5 g/L) 10 min; 4°C), and 6-keto PGF1 was quantified in the superna- α medium supplemented with heat-inactivated FCS (10%, v/v), tant using a 6-keto PGF1 High Sensitivity EIA Kit (Assay Mol Cancer Ther 2009;8(8). August 2009 Downloaded from mct.aacrjournals.org on September 24, 2021. © 2009 American Association for Cancer Research.
Load more

Recommended publications
  • Non-Steroidal Anti-Inflammatory Agents – Benefits and New Developments for Cancer Pain
    Carr_subbed.qxp 22/5/09 09:49 Page 18 Supportive Oncology Non-steroidal Anti-inflammatory Agents – Benefits and New Developments for Cancer Pain a report by Daniel B Carr1 and Marie Belle D Francia2 1. Saltonstall Professor of Pain Research; 2. Special Scientific Staff, Department of Anesthesiology, Tufts Medical Center DOI: 10.17925/EOH.2008.04.2.18 Pain is one of the complications of cancer that patients most fear, and This article surveys the current role of NSAIDs in the management of its multifactorial aetiology makes it one of the most challenging cancer pain and elucidates newly recognised mechanisms that may conditions to treat.1 A systematic review of epidemiological studies on provide a foundation for the next generation of NSAIDs for analgesia cancer pain published between 1982 and 2001 revealed cancer pain for cancer patients. prevalence rates of at least 14%.2 A more recent systematic review identified prevalence rates of cancer pain in as many as one-third of Mechanism of Analgesic Effects patients after curative treatment and two-thirds of patients NSAIDs are a structurally diverse group of compounds known to undergoing treatment regardless of the stage of disease. The wide prevent the formation of prostanoids (prostaglandins and variation in published prevalence rates is due to heterogeneity of the thromboxane) from arachidonic acid through the inhibition of the populations studied, diverse settings, site of primary cancer and stage enzyme cyclo-oxygenase (COX; see Table 1). COX has two isoenzymes: and methodology used to ascertain prevalence.1 COX-1 is found ubiquitously in most tissues and produces prostaglandins and thromboxane, while COX-2 is located in certain A multimodal approach to the treatment of cancer pain that deploys tissues (brain, blood vessels and so on) and its expression increases both pharmacological and non-pharmacological methods may be during inflammation or fever.
    [Show full text]
  • Chemical Composition and Product Quality Control of Turmeric
    Stephen F. Austin State University SFA ScholarWorks Faculty Publications Agriculture 2011 Chemical composition and product quality control of turmeric (Curcuma longa L.) Shiyou Li Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Wei Yuan Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Guangrui Deng Ping Wang Stephen F Austin State University, Arthur Temple College of Forestry and Agriculture, [email protected] Peiying Yang See next page for additional authors Follow this and additional works at: http://scholarworks.sfasu.edu/agriculture_facultypubs Part of the Natural Products Chemistry and Pharmacognosy Commons, and the Pharmaceutical Preparations Commons Tell us how this article helped you. Recommended Citation Li, Shiyou; Yuan, Wei; Deng, Guangrui; Wang, Ping; Yang, Peiying; and Aggarwal, Bharat, "Chemical composition and product quality control of turmeric (Curcuma longa L.)" (2011). Faculty Publications. Paper 1. http://scholarworks.sfasu.edu/agriculture_facultypubs/1 This Article is brought to you for free and open access by the Agriculture at SFA ScholarWorks. It has been accepted for inclusion in Faculty Publications by an authorized administrator of SFA ScholarWorks. For more information, please contact [email protected]. Authors Shiyou Li, Wei Yuan, Guangrui Deng, Ping Wang, Peiying Yang, and Bharat Aggarwal This article is available at SFA ScholarWorks: http://scholarworks.sfasu.edu/agriculture_facultypubs/1 28 Pharmaceutical Crops, 2011, 2, 28-54 Open Access Chemical Composition and Product Quality Control of Turmeric (Curcuma longa L.) ,1 1 1 1 2 3 Shiyou Li* , Wei Yuan , Guangrui Deng , Ping Wang , Peiying Yang and Bharat B. Aggarwal 1National Center for Pharmaceutical Crops, Arthur Temple College of Forestry and Agriculture, Stephen F.
    [Show full text]
  • In Vitro Immunopharmacological Profiling of Ginger (Zingiber Officinale Roscoe)
    Research Collection Doctoral Thesis In vitro immunopharmacological profiling of ginger (Zingiber officinale Roscoe) Author(s): Nievergelt, Andreas Publication Date: 2011 Permanent Link: https://doi.org/10.3929/ethz-a-006717482 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH Nr. 19591 In Vitro Immunopharmacological Profiling of Ginger (Zingiber officinale Roscoe) ABHANDLUNG zur Erlangung des Titels DOKTOR DER WISSENSCHAFTEN der ETH ZÜRICH vorgelegt von Andreas Nievergelt Eidg. Dipl. Apotheker, ETH Zürich geboren am 18.12.1978 von Schleitheim, SH Angenommen auf Antrag von Prof. Dr. Karl-Heinz Altmann, Referent Prof. Dr. Jürg Gertsch, Korreferent Prof. Dr. Michael Detmar, Korreferent 2011 Table of Contents Summary 6 Zusammenfassung 7 Acknowledgements 8 List of Abbreviations 9 1. Introduction 13 1.1 Ginger (Zingiber officinale) 13 1.1.1 Origin 14 1.1.2 Description 14 1.1.3 Chemical Constituents 15 1.1.4 Traditional and Modern Pharmaceutical Use of Ginger 17 1.1.5 Reported In Vitro Effects 20 1.2 Immune System and Inflammation 23 1.2.1 Innate and Adaptive Immunity 24 1.2.2 Cytokines in Inflammation 25 1.2.3 Pattern Recognition Receptors 29 1.2.4 Toll-Like Receptors 30 1.2.5 Serotonin 1A and 3 Receptors 32 1.2.6 Phospholipases A2 33 1.2.7 MAP Kinases 36 1.2.8 Fighting Inflammation, An Ongoing Task 36 1.2.9 Inflammation Assays Using Whole Blood 38 1.3 Arabinogalactan-Proteins 39 1.3.1 Origin and Biological Function of AGPs 40 1.3.2 Effects on Animals 41 1.3.3 The ‘Immunostimulation’ Theory 42 1/188 2.
    [Show full text]
  • Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development
    molecules Article Licofelone-DPPC Interactions: Putting Membrane Lipids on the Radar of Drug Development Catarina Pereira-Leite 1,2 , Daniela Lopes-de-Campos 1, Philippe Fontaine 3 , Iolanda M. Cuccovia 2, Cláudia Nunes 1 and Salette Reis 1,* 1 LAQV, REQUIMTE, Departamento de Ciências Químicas, Faculdade de Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal; [email protected] (C.P.-L.); [email protected] (D.L.-d.-C.); [email protected] (C.N.) 2 Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, Av. Prof. Lineu Prestes, 748, 05508-000 São Paulo, Brazil; [email protected] 3 Synchrotron SOLEIL, L’Orme des Merisiers, Saint Aubin, BP48, 91192 Gif-sur-Yvette, France; [email protected] * Correspondence: [email protected]; Tel.: +351-220-428-672 Academic Editors: Maria Emília De Sousa, Honorina Cidade and Carlos Manuel Afonso Received: 19 December 2018; Accepted: 30 January 2019; Published: 31 January 2019 Abstract: (1) Background: Membrane lipids have been disregarded in drug development throughout the years. Recently, they gained attention in drug design as targets, but they are still disregarded in the latter stages. Thus, this study aims to highlight the relevance of considering membrane lipids in the preclinical phase of drug development. (2) Methods: The interactions of a drug candidate for clinical use (licofelone) with a membrane model system made of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) were evaluated by combining Langmuir isotherms, Brewster angle microscopy (BAM), polarization-modulation infrared reflection-absorption spectroscopy (PM-IRRAS), and grazing-incidence X-ray diffraction (GIXD) measurements.
    [Show full text]
  • Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic
    ANTICANCER RESEARCH 37 : 161-168 (2017) doi:10.21873/anticanres.11301 Hyperforin Inhibits Cell Growth by Inducing Intrinsic and Extrinsic Apoptotic Pathways in Hepatocellular Carcinoma Cells I-TSANG CHIANG 1,2,3* , WEI-TING CHEN 4* , CHIH-WEI TSENG 5, YEN-CHUNG CHEN 2,6 , YU-CHENG KUO 7, BI-JHIH CHEN 8, MAO-CHI WENG 9, HWAI-JENG LIN 10,11# and WEI-SHU WANG 2,12,13# Departments of 1Radiation Oncology, 6Pathology, and 13 Medicine, and 2Cancer Medical Care Center, National Yang-Ming University Hospital, Yilan, Taiwan, R.O.C.; 3Department of Radiological Technology, Central Taiwan University of Science and Technology, Taichung, Taiwan, R.O.C.; 4Department of Psychiatry, Zuoying Branch of Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, R.O.C.; 5Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan, R.O.C.; 7Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.; 8Department of Laboratory Medicine, Changhua Christian Hospital, Changhua Christian Medical Foundation, Changhua, Taiwan, R.O.C.; 9Institute of Nuclear Energy Research, Atomic Energy Council, Taoyuan, Taiwan, R.O.C.; 10 Department of Internal Medicine, Division of Gastroenterology and Hepatology, College of Medicine, School of Medicine, Taipei Medical University, Taipei, Taiwan, R.O.C.; 11 Department of Internal Medicine, Division of Gastroenterology and Hepatology, Shuang-Ho Hospital, New Taipei, Taiwan, R.O.C.; 12 National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C. Abstract. The aim of the present study was to investigate the (c-FLIP), X-linked inhibitor of apoptosis protein (XIAP), antitumor effect and mechanism of action of hyperforin in myeloid cell leukemia 1(MCL1), and cyclin-D1] were hepatocellular carcinoma (HCC) SK-Hep1 cells in vitro.
    [Show full text]
  • Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: a Comprehensive Review
    Kinesiology and Nutrition Sciences Faculty Publications Kinesiology and Nutrition Sciences 4-28-2021 Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: A Comprehensive Review Paramita Basu University of Pittsburgh School of Medicine Camelia Maier Texas Woman's University Arpita Basu University of Nevada, Las Vegas, [email protected] Follow this and additional works at: https://digitalscholarship.unlv.edu/kns_fac_articles Part of the Molecular Biology Commons Repository Citation Basu, P., Maier, C., Basu, A. (2021). Effects of Curcumin and Its Different Formulations in Preclinical and Clinical Studies of Peripheral Neuropathic and Postoperative Pain: A Comprehensive Review. International Journal of Molecular Sciences, 22(9), 1-36. http://dx.doi.org/10.3390/ijms22094666 This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/ or on the work itself. This Article has been accepted for inclusion in Kinesiology and Nutrition Sciences Faculty Publications by an authorized administrator of Digital Scholarship@UNLV. For more information, please contact [email protected].
    [Show full text]
  • WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/142184 Al 26 September 2013 (26.09.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 33/16 (2006.01) A61K 31/7048 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, A61K 33/14 (2006.01) A61K 31/70 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, A61K 33/18 (2006.01) A61K 31/4196 (2006.01) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (21) International Application Number: RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, PCT/US20 13/030788 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (22) International Filing Date: ZM, ZW. 13 March 2013 (13.03.2013) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/612,689 19 March 2012 (19.03.2012) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: YALE UNIVERSITY [US/US]; Two Whitney TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Avenue, New Haven, CT 065 10 (US).
    [Show full text]
  • Curcumin: Significance in Treating Diseases
    Review Article Advances in Bioengineering & Biomedical Science Research Curcumin: Significance in Treating Diseases Abbaraju Krishnasailaja* and Madiha Fatima *Corresponding author Abbaraju Krishnasailaja, Department of Pharmaceutics, RBVRR Women’s College of Pharmacy, Barkatpura, Hyderabad- 500027, India, Tel: 040 Department of Pharmaceutics, RBVRR Women’s College of 27560365; E-mail: [email protected] Pharmacy, India Submitted: 05 June 2018; Accepted: 12 June 2018; Published: 02 July 2018 Abstract Turmeric (Curcuma longa) is extensively used as a spice, food preservative and coloring material in India, China and South East Asia. It has been used in traditional medicine as a household remedy for various diseases, including biliary disorders, anorexia, cough, diabetic wounds, hepatic disorders, rheumatism and sinusitis. For the last few decades, extensive work has been done to establish the biological activities and pharmacological actions of turmeric and its extracts. Curcumin (diferuloylmethane), the main yellow bioactive component of turmeric has been shown to have a wide spectrum of biological actions. These include its anti-inflammatory, antioxidant, anticarcinogenic, antimutagenic, anticoagulant, antifertility, antidiabetic, antibacterial, antifungal, antiprotozoal, antiviral,anti-fibrotic, antivenom, antiulcer, hypotensive and hypocholesteremic activities. Its anticancer effect is mainly mediated through induction of apoptosis. Its anti-inflammatory, anticancer and antioxidant roles may be clinically exploited to control rheumatism, carcinogenesis and oxidative stress-related pathogenesis. Clinically, curcumin has already been used to reduce post-operative inflammation. Introduction golden hamsters. The Indian Solid Gold Turmeric 4. Curcumin also increases mucin secretion in rabbits. Curcumin is extracted from turmeric which is derived from rhizome of 5. Curcumin, the ethanol extract of the rhizomes, sodium plant curcuma longa. Curcuminoids give turmeric its characteristics curcuminate, [feruloyl-(4-hydroxycinnamoyl)-methane] yellow color.
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Synaptic Action of Anandamide and Related Substances in Mammalian Brain
    SYNAPTIC ACTION OF ANANDAMIDE AND RELATED SUBSTANCES IN MAMMALIAN BRAIN by Chengyong Liao M.Sc., Sichuan University, 1991 B.Sc., Sichuan University, 1984 THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY Inthe Department of Biological Sciences © Chengyong Liao 2007 SIMON FRASER UNIVERSITY 2007 All rights reserved. This work may not be reproduced in whole or in part, by photocopy or other means, without permission ofthe author. APPROVAL Name: Chengyong Liao Degree: Doctor of Philosophy Title of Thesis: Synaptic Actions of Anandamide and Related Substances in Mammalian Brain Examining Committee: Chair: Dr. Z. Punja Professor ofDepartment ofBiological Sciences, SFU. Dr. R. A. Nicholson Senior Supervisor Associate Professor ofDepartment ofBiological Sciences, SFU. Dr. C. J. Kennedy, Supervisor Associate Professor of Department ofBiological Sciences, SFU Dr. F. C. P. Law, Supervisor Professor ofDepartment ofBiological Sciences, SFU Dr. M. A. Silverman Public Examiner Associate Professor ofDepartment ofBiological Sciences, SFU Dr. J. Church External Examiner Professor ofDepartment ofCellular and Physiological Sciences, UBC Date Defended/Approved: 11 SIMON FRASER UNIVERSITY LIBRARY Declaration of Partial Copyright Licence The author, whose copyright is declared on the title page of this work, has granted to Simon Fraser University the right to lend this thesis, project or extended essay to users of the Simon Fraser University Library, and to make partial or single copies only for such users or
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]